{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:18Z","timestamp":1760028858322,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ahj.2005.09.007","type":"journal-article","created":{"date-parts":[[2006,9,9]],"date-time":"2006-09-09T07:17:15Z","timestamp":1157786235000},"page":"149-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial"],"prefix":"10.1016","volume":"152","author":[{"given":"Vivek","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitinder S.","family":"Gurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingfei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J.","family":"Desmet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal S.","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Bittl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Feit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2005.09.007_bib1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"The EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.007_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"The EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.007_bib3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","article-title":"Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"284","author":"Bhatt","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.09.007_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0735-1097(97)00110-1","volume":"30","author":"Lincoff","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.09.007_bib5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0735-1097(01)01290-6","article-title":"Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention","volume":"37","author":"Anderson","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.09.007_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2005.09.007_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.09.007_bib8","first-page":"1792","article-title":"Economic evaluation of bivalirudin with provisional glycoprotein IIB\/IIIA inhibition versus heparin with routine glycoprotein IIB\/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial","volume":"44","author":"Cohen","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.09.007_bib9","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1161\/01.CIR.92.9.2480","article-title":"In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators","volume":"92","author":"Cohen","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.09.007_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1067\/mhj.2003.3","article-title":"Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials","volume":"145","author":"Taira","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2005.09.007_bib11","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","article-title":"Benefit of glycoprotein IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin T\u2013positive status: the paragon-B troponin T substudy","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.09.007_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.007_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/01.CIR.90.3.1522","article-title":"Direct thrombin inhibitors in cardiovascular medicine","volume":"90","author":"Lefkovits","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.09.007_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.2830260307","article-title":"Effect of heparin on platelet count and platelet aggregation","volume":"26","author":"Shojania","year":"1987","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ahj.2005.09.007_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III\u2013independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"issue":"Suppl B","key":"10.1016\/j.ahj.2005.09.007_bib16","first-page":"2B","article-title":"Acute coronary syndromes: a focus on thrombin","volume":"14","author":"Weitz","year":"2002","journal-title":"J Invasive Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305008628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305008628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:28:10Z","timestamp":1757568490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870305008628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0002870305008628"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2005.09.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2005.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}